Kardigan targets $1.4B valuation in U.S. IPO

Heart drug developer Kardigan is targeting a $1.4 billion valuation in its U.S. initial public offering. The company is seeking to raise capital by selling shares to public investors. The IPO would value the biotech firm at approximately $1.4 billion.